Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Olga Bogdanova

Neurology Gadsden, AL Medical Doctor

NPI 1700955846 CMS profile 924358

820 Goodyear Ave, Gadsden, AL 35903

Open in the dashboard

General payments

$6,657

364 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Olga Bogdanova of Gadsden, AL is reported in the CMS Open Payments database as having received $6,657 across 364 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $836 37
2024 General $1,066 48
2023 General $811 35
2022 General $954 52
2021 General $527 34
2020 General $969 60
2019 General $1,493 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olga Bogdanova
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Olga Bogdanova were reported at $836. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Olga Bogdanova Neurology median Middle half National median
2019 $1,493 $474 $118–$2,177 $163
2020 $969 $367 $82–$2,309 $114
2021 $527 $438 $104–$2,547 $132
2022 $954 $442 $103–$2,388 $149
2023 $811 $464 $119–$2,312 $160
2024 $1,066 $468 $119–$2,323 $164
2025 $836 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $981 64 payments
  2. Supernus Pharmaceuticals, Inc. $538 42 payments
  3. Harmony Biosciences LLC $530 22 payments
  4. CSL Behring $457 12 payments
  5. Lundbeck LLC $330 16 payments
  6. Eisai Inc. $316 15 payments
  7. UCB, Inc. $296 17 payments
  8. Celgene Corporation $294 5 payments
  9. Amgen Inc. $259 15 payments
  10. Pfizer Inc. $245 17 payments
  11. Other $2,409 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,657 364 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $728 46 payments
  2. TROKENDI XR $477 38 payments
  3. Hizentra $457 12 payments
  4. VUMERITY Neurology $452 26 payments
  5. AIMOVIG $389 21 payments
  6. ZEPOSIA $351 10 payments
  7. VUMERITY Neurology $318 21 payments
  8. AVONEX $248 18 payments
  9. Leqembi $231 10 payments
  10. WAKIX $207 10 payments
  11. Other $4,161 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

7,455

Median for Neurology: 833

Drug cost

$1,986,885

Median for Neurology: $202,670

Branded share of claims

23.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 36 $431,188
Ingrezza Valbenazine Tosylate Brand 25 $293,092
Austedo Deutetrabenazine Brand 14 $201,231
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 11 $164,623
Dimethyl Fumarate Generic 23 $101,047
Emgality Pen Galcanezumab-Gnlm Brand 134 $97,692
Nurtec Odt Rimegepant Sulfate Brand 62 $61,682
Ubrelvy Ubrogepant Brand 59 $60,477
Botox Onabotulinumtoxina Brand 32 $40,029
Neupro Rotigotine Brand 39 $36,295

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$142,932

Medicare's payments for the services billed

Medicare patients

627

Average age 72

Services billed

2,666

354 women, 273 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 40%
Depression 36%
Ischemic heart disease 35%
Chronic kidney disease 35%
Heart failure 22%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $207
$207 — —
Leqembi
  • Eisai Inc. $153
$153 — —
ZEPOSIA
  • Celgene Corporation $127
$127 — —
Hizentra
  • CSL Behring $112
$112 — —
VYEPTI
  • Lundbeck LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

364 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record